iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares

Key Points

• iBio CFO Felipe Duran purchased 24,835 shares on March 19 at an average price of $2.02 (≈$50,166.70), boosting his holdings to 35,974 shares—a 222.96% increase—per an SEC filing.
• Stock snapshot: iBio opened at $2.11, with a 52-week range of $0.56–$4.86, a market cap of about $72.7 million and a negative trailing P/E of -2.11.
• Analyst sentiment: The consensus rating is "Buy" with an average target price of $4.75, though individual analyst opinions vary from "sell" to "strong-buy."

iBio, Inc. (NASDAQ:IBIO - Get Free Report) CFO Felipe Duran acquired 24,835 shares of the stock in a transaction dated Thursday, March 19th. The stock was acquired at an average price of $2.02 per share, with a total value of $50,166.70. Following the completion of the acquisition, the chief financial officer owned 35,974 shares in the company, valued at approximately $72,667.48. The trade was a 222.96% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

iBio Stock Up 0.2%

Shares of iBio stock opened at $2.11 on Monday. iBio, Inc. has a 52-week low of $0.56 and a 52-week high of $4.86. The firm has a fifty day simple moving average of $2.38. The stock has a market cap of $72.72 million, a PE ratio of -2.11 and a beta of 1.18.

iBio (NASDAQ:IBIO - Get Free Report) last released its earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01).

Hedge Funds Weigh In On iBio

Hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in iBio in the fourth quarter valued at $71,000. Ikarian Capital LLC raised its holdings in iBio by 55.0% in the 4th quarter. Ikarian Capital LLC now owns 957,062 shares of the company's stock worth $1,847,000 after purchasing an additional 339,735 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in shares of iBio in the 4th quarter worth about $4,300,000. Balyasny Asset Management L.P. lifted its position in shares of iBio by 10,440.2% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,096,179 shares of the company's stock worth $2,116,000 after purchasing an additional 1,085,779 shares during the period. Finally, Boothbay Fund Management LLC boosted its stake in shares of iBio by 43.8% during the 4th quarter. Boothbay Fund Management LLC now owns 254,412 shares of the company's stock valued at $491,000 after purchasing an additional 77,550 shares in the last quarter. 7.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IBIO has been the subject of a number of analyst reports. Wall Street Zen lowered iBio from a "hold" rating to a "sell" rating in a research note on Saturday. Lifesci Capital upgraded shares of iBio to a "strong-buy" rating in a report on Thursday, December 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of iBio in a research report on Monday, December 29th. Chardan Capital restated a "buy" rating and issued a $5.00 price objective on shares of iBio in a research report on Wednesday, March 18th. Finally, JonesTrading assumed coverage on shares of iBio in a research note on Tuesday, March 3rd. They set a "buy" rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $4.75.

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.